Clinical Trial

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

Name: A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) — clinical trial record (NCT07700238)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ROMISTER

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This Phase 3 study is designed to evaluate the efficacy and safety of romiplostim in combination with predniso(lo)ne compared with predniso(lo)ne alone in adults with previously untreated Primary Immune Thrombocytopenia (ITP).

Trial Details

NCT Number	NCT07700238
Lead Sponsor	Amgen
Conditions	Primary Immune Thrombocytopenia
Enrollment	126 participants
Start Date	2026-07-20
Primary Completion	2029-09-14 (estimated)
Study Completion	2029-09-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-13